Search

Your search keyword '"Szeimies, Rolf‐Markus"' showing total 638 results
Start Over Author "Szeimies, Rolf‐Markus"
638 results on '"Szeimies, Rolf‐Markus"'

4. Efficacy and safety of ingenol disoxate gel in field treatment of actinic keratosis on full face, scalp or large area (250 cm2) on the chest: results of four phase 3 randomized controlled trials

Author

Berman, Brian, Bukhalo, Michael, Hanke, C William, Jarner, Mikala Fiig, Larsson, Thomas, Siegel, Daniel M, Skov, Torsten, and Szeimies, Rolf-Markus

Subjects
ingenol disoxate, actinic keratosis, ingenol, cancer
Abstract

Introduction: Actinic keratosis (AK) is a skin condition arising from chronic exposure to ultraviolet light and may lead to the development of malignancies. This trial aimed to evaluate efficacy and safety of ingenol disoxate gel (IngDsx, 0.018% for face/chest [FC]; 0.037% for scalp [S]), versus vehicle. Methods: Four identical phase 3 trials in patients with AK on the full face/up to 250cm2 of chest or full balding scalp, with an initial 8-week period and 12-month follow-up, were conducted. FC and S trials were pooled for analysis. The primary endpoint was complete clearance at Week 8. Results: Across trials, 616 patients were randomized to FC and 626 to S, with 410 and 420 assigned to receive IngDsx, respectively. In the FC and S trials, 25.9% and 24.5% of patients in the IngDsx group, respectively, achieved the primary endpoint. IngDsx was relatively well tolerated. During extended follow-up, there were more identified non-melanoma skin malignancies in the IngDsx group than vehicle group; HR: 2.38 (95% CI: 1.28, 4.41). Conclusion: Treatment with IngDsx was superior to vehicle on all clinical endpoints, patient-reported and cosmetic outcomes. During the 12-month follow-up, slightly increased skin malignancies in the treatment area were identified, potentially due to unintentional detection bias.

Published
2020

5. Diseases of Mineral Metabolism

Author

Szeimies, Rolf-Markus, Dirschka, Thomas, Kaufmann, Roland, Section editor, Plewig, Gerd, editor, French, Lars, editor, Ruzicka, Thomas, editor, Kaufmann, Roland, editor, and Hertl, Michael, editor

Published
2022
Full Text
View/download PDF

7. German S3 guideline “actinic keratosis and cutaneous squamous cell carcinoma” – Long version of the update 2023

Author

Leiter, Ulrike, Heppt, Markus V., Steeb, Theresa, Alter, Mareike, Amaral, Teresa, Bauer, Andrea, Bechara, Falk G., Becker, Jürgen C., Breitbart, Eckhard W., Breuninger, Helmut, Diepgen, Thomas, Dirschka, Thomas, Eigentler, Thomas, El Gammal, A.K. Stephan, Felcht, Moritz, Flaig, Michael J., Follmann, Markus, Fritz, Klaus, Grabbe, Stephan, Greinert, Rüdiger, Gutzmer, Ralf, Hauschild, Axel, Hillen, Uwe, Ihrler, Stephan, John, Swen Malte, Kofler, Lukas, Koelbl, Oliver, Krause-Bergmann, Albrecht, Kraywinkel, Klaus, Krohn, Steffen, Langer, Thomas, Loquai, Carmen, Löser, Christoph R., Mohr, Peter, Nashan, Dorothée, Nothacker, Monika, Pfannenberg, Christina, Salavastru, Carmen, Schmitz, Lutz, Stockfleth, Eggert, Szeimies, Rolf-Markus, Ulrich, Claas, Voelter-Mahlknecht, Susanne, Vordermark, Dirk, Weichenthal, Michael, Welzel, Julia, Wermker, Kai, Wiegand, Susanne, Garbe, Claus, and Berking, Carola

Published
2023
Full Text
View/download PDF

8. Photodynamische Therapie in der Dermatologie: Bewährte und neue Indikationen.

Author

Balakirski, Galina, Lehmann, Percy, Szeimies, Rolf‐Markus, and Hofmann, Silke C.

Abstract

Copyright of Journal der Deutschen Dermatologischen Gesellschaft is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024
Full Text
View/download PDF

9. Photodynamic therapy in dermatology: established and new indications.

Author

Balakirski, Galina, Lehmann, Percy, Szeimies, Rolf‐Markus, and Hofmann, Silke C.

Abstract

Summary: Photodynamic therapy (PDT) is internationally established as an approved treatment option for in situ forms of keratinocytic skin cancer (actinic keratoses, Bowen's disease, basal cell carcinoma). For these indications, there are standardized treatment protocols using narrow‐spectrum light sources or (artificial) daylight, the use of which is associated with successful healing, a low rate of lesion recurrence, and a very good cosmetic result. Daylight PDT is superior to conventional PDT in terms of significantly less pain and associated higher patient acceptance. Newer indications, for which no approval has yet been granted, but which nevertheless have sufficient evidence of efficacy according to the study situation, are inflammatory (lichen sclerosus, acne) and infectious dermatoses (viral warts, cutaneous leishmaniasis, atypical mycobacteriosis). In addition, PDT is increasingly being used in aesthetic dermatology with the aim of skin rejuvenation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Optimization of the Treatment of Squamous Cell Carcinoma Cells by Combining Photodynamic Therapy with Cold Atmospheric Plasma.

Author

Karrer, Sigrid, Unger, Petra, Spindler, Nina, Szeimies, Rolf-Markus, Bosserhoff, Anja Katrin, Berneburg, Mark, and Arndt, Stephanie

Subjects
COLD atmospheric plasmas, RED light, SQUAMOUS cell carcinoma, ACTINIC keratosis, IONIZED gases
Abstract

Actinic keratosis (AK) is characterized by a reddish or occasionally skin-toned rough patch on sun-damaged skin, and it is regarded as a precursor to squamous cell carcinoma (SCC). Photodynamic therapy (PDT), utilizing 5-aminolevulinic acid (ALA) along with red light, is a recognized treatment option for AK that is limited by the penetration depth of light and the distribution of the photosensitizer into the skin. Cold atmospheric plasma (CAP) is a partially ionized gas with permeability-enhancing and anti-cancer properties. This study analyzed, in vitro, whether a combined treatment of CAP and ALA-PDT may improve the efficacy of the treatment. In addition, the effect of the application sequence of ALA and CAP was investigated using in vitro assays and the molecular characterization of human oral SCC cell lines (SCC-9, SCC-15, SCC-111), human cutaneous SCC cell lines (SCL-1, SCL-2, A431), and normal human epidermal keratinocytes (HEKn). The anti-tumor effect was determined by migration, invasion, and apoptosis assays and supported the improved efficacy of ALA-PDT in combination with CAP. However, the application sequence ALA-CAP–red light seems to be more efficacious than CAP-ALA–red light, which is probably due to increased intracellular ROS levels when ALA is applied first, followed by CAP and red light treatment. Furthermore, the expression of apoptosis- and senescence-related molecules (caspase-3, -6, -9, p16INK4a, p21CIP1) was increased, and different genes of the junctional network (ZO-1, CX31, CLDN1, CTNNB1) were induced after the combined treatment of CAP plus ALA-PDT. HEKn, however, were much less affected than SCC cells. Overall, the results show that CAP may improve the anti-tumor effects of conventional ALA-PDT on SCC cells. Whether this combined application is successful in treating AK in vivo has to be carefully examined in follow-up studies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines

Author

Peris, Ketty, Fargnoli, Maria Concetta, Garbe, Claus, Kaufmann, Roland, Bastholt, Lars, Seguin, Nicole Basset, Bataille, Veronique, Marmol, Veronique del, Dummer, Reinhard, Harwood, Catherine A., Hauschild, Axel, Höller, Christoph, Haedersdal, Merete, Malvehy, Josep, Middleton, Mark R., Morton, Colin A., Nagore, Eduardo, Stratigos, Alexander J., Szeimies, Rolf-Markus, Tagliaferri, Luca, Trakatelli, Myrto, Zalaudek, Iris, Eggermont, Alexander, and Grob, Jean Jacques

Published
2019
Full Text
View/download PDF

16. S3‐Leitlinie “Aktinische Keratose und Plattenepithelkarzinom der Haut“ – Update 2023, Teil 2: Epidemiologie und Ätiologie, Diagnostik, Therapie des invasiven Plattenepithelkarzinoms der Haut, Nachsorge und Prävention

Author

Leiter, Ulrike, primary, Heppt, Markus V., additional, Steeb, Theresa, additional, Alter, Mareike, additional, Amaral, Teresa, additional, Bauer, Andrea, additional, Bechara, Falk G., additional, Becker, Jürgen C., additional, Breitbart, Eckhard W., additional, Breuninger, Helmut, additional, Diepgen, Thomas, additional, Dirschka, Thomas, additional, Eigentler, Thomas, additional, El Gammal, A. K. Stephan, additional, Felcht, Moritz, additional, Flaig, Michael J., additional, Follmann, Markus, additional, Fritz, Klaus, additional, Grabbe, Stephan, additional, Greinert, Rüdiger, additional, Gutzmer, Ralf, additional, Hauschild, Axel, additional, Hillen, Uwe, additional, Ihrler, Stephan, additional, John, Swen Malte, additional, Kofler, Lukas, additional, Koelbl, Oliver, additional, Krause‐Bergmann, Albrecht, additional, Kraywinkel, Klaus, additional, Krohn, Steffen, additional, Langer, Thomas, additional, Loquai, Carmen, additional, Löser, Christoph R., additional, Mohr, Peter, additional, Nashan, Dorothée, additional, Nothacker, Monika, additional, Pfannenberg, Christina, additional, Salavastru, Carmen, additional, Schmitz, Lutz, additional, Stockfleth, Eggert, additional, Szeimies, Rolf‐Markus, additional, Ulrich, Claas, additional, Voelter‐Mahlknecht, Susanne, additional, Vordermark, Dirk, additional, Weichenthal, Michael, additional, Welzel, Julia, additional, Wermker, Kai, additional, Wiegand, Susanne, additional, Garbe, Claus, additional, and Berking, Carola, additional

Published
2023
Full Text
View/download PDF

17. S3 guideline „actinic keratosis and cutaneous squamous cell carcinoma“ – update 2023, part 2: epidemiology and etiology, diagnostics, surgical and systemic treatment of cutaneous squamous cell carcinoma (cSCC), surveillance and prevention

Author

Leiter, Ulrike, primary, Heppt, Markus V., additional, Steeb, Theresa, additional, Alter, Mareike, additional, Amaral, Teresa, additional, Bauer, Andrea, additional, Bechara, Falk G., additional, Becker, Jürgen C., additional, Breitbart, Eckhard W., additional, Breuninger, Helmut, additional, Diepgen, Thomas, additional, Dirschka, Thomas, additional, Eigentler, Thomas, additional, ElGammal, A. K. Stephan, additional, Felcht, Moritz, additional, Flaig, Michael J., additional, Follmann, Markus, additional, Fritz, Klaus, additional, Grabbe, Stephan, additional, Greinert, Rüdiger, additional, Gutzmer, Ralf, additional, Hauschild, Axel, additional, Hillen, Uwe, additional, Ihrler, Stephan, additional, John, Swen Malte, additional, Kofler, Lukas, additional, Koelbl, Oliver, additional, Krause‐Bergmann, Albrecht, additional, Kraywinkel, Klaus, additional, Krohn, Steffen, additional, Langer, Thomas, additional, Loquai, Carmen, additional, Löser, Christoph R., additional, Mohr, Peter, additional, Nashan, Dorothée, additional, Nothacker, Monika, additional, Pfannenberg, Christina, additional, Salavastru, Carmen, additional, Schmitz, Lutz, additional, Stockfleth, Eggert, additional, Szeimies, Rolf‐Markus, additional, Ulrich, Claas, additional, Voelter‐Mahlknecht, Susanne, additional, Vordermark, Dirk, additional, Weichenthal, Michael, additional, Welzel, Julia, additional, Wermker, Kai, additional, Wiegand, Susanne, additional, Garbe, Claus, additional, and Berking, Carola, additional

Published
2023
Full Text
View/download PDF

18. S3‐Leitlinie “Aktinische Keratose und Plattenepithelkarzinom der Haut“ – Update 2023, Teil 1: Therapie der aktinischen Keratose, Morbus Bowen, Cheilitis actinica, berufsbedingte Erkrankung und Versorgungsstrukturen

Author

Heppt, Markus V., primary, Leiter, Ulrike, additional, Steeb, Theresa, additional, Alter, Mareike, additional, Amaral, Teresa, additional, Bauer, Andrea, additional, Bechara, Falk G., additional, Becker, Jürgen C., additional, Breitbart, Eckhard W., additional, Breuninger, Helmut, additional, Diepgen, Thomas, additional, Dirschka, Thomas, additional, Eigentler, Thomas, additional, El Gammal, A. K. Stephan, additional, Felcht, Moritz, additional, Flaig, Michael J., additional, Follmann, Markus, additional, Fritz, Klaus, additional, Grabbe, Stephan, additional, Greinert, Rüdiger, additional, Gutzmer, Ralf, additional, Hauschild, Axel, additional, Hillen, Uwe, additional, Ihrler, Stephan, additional, John, Swen Malte, additional, Kofler, Lukas, additional, Koelbl, Oliver, additional, Krause‐Bergmann, Albrecht, additional, Kraywinkel, Klaus, additional, Krohn, Steffen, additional, Langer, Thomas, additional, Loquai, Carmen, additional, Löser, Christoph R., additional, Mohr, Peter, additional, Nashan, Dorothée, additional, Nothacker, Monika, additional, Pfannenberg, Christina, additional, Salavastru, Carmen, additional, Schmitz, Lutz, additional, Stockfleth, Eggert, additional, Szeimies, Rolf‐Markus, additional, Ulrich, Claas, additional, Voelter‐Mahlknecht, Susanne, additional, Vordermark, Dirk, additional, Weichenthal, Michael, additional, Welzel, Julia, additional, Wermker, Kai, additional, Wiegand, Susanne, additional, Garbe, Claus, additional, and Berking, Carola, additional

Published
2023
Full Text
View/download PDF

19. S3 guideline „actinic keratosis and cutaneous squamous cell carcinoma“– update 2023, part 1: treatment of actinic keratosis, actinic cheilitis, cutaneous squamous cell carcinoma in situ (Bowen's disease), occupational disease and structures of care

Author

Heppt, Markus V., primary, Leiter, Ulrike, additional, Steeb, Theresa, additional, Alter, Mareike, additional, Amaral, Teresa, additional, Bauer, Andrea, additional, Bechara, Falk G., additional, Becker, Jürgen C., additional, Breitbart, Eckhard W., additional, Breuninger, Helmut, additional, Diepgen, Thomas, additional, Dirschka, Thomas, additional, Eigentler, Thomas, additional, El Gammal, A. K. Stephan, additional, Felcht, Moritz, additional, Flaig, Michael J., additional, Follmann, Markus, additional, Fritz, Klaus, additional, Grabbe, Stephan, additional, Greinert, Rüdiger, additional, Gutzmer, Ralf, additional, Hauschild, Axel, additional, Hillen, Uwe, additional, Ihrler, Stephan, additional, John, Swen Malte, additional, Kofler, Lukas, additional, Koelbl, Oliver, additional, Krause‐Bergmann, Albrecht, additional, Kraywinkel, Klaus, additional, Krohn, Steffen, additional, Langer, Thomas, additional, Loquai, Carmen, additional, Löser, Christoph R., additional, Mohr, Peter, additional, Nashan, Dorothée, additional, Nothacker, Monika, additional, Pfannenberg, Christina, additional, Salavastru, Carmen, additional, Schmitz, Lutz, additional, Stockfleth, Eggert, additional, Szeimies, Rolf‐Markus, additional, Ulrich, Claas, additional, Voelter‐Mahlknecht, Susanne, additional, Vordermark, Dirk, additional, Weichenthal, Michael, additional, Welzel, Julia, additional, Wermker, Kai, additional, Wiegand, Susanne, additional, Garbe, Claus, additional, and Berking, Carola, additional

Published
2023
Full Text
View/download PDF

23. A Review of MAL-PDT for the Treatment Strategy of Actinic Keratosis:Broader Clinical Perspectives Beyond the Data and Guideline Recommendations

Author

Szeimies, Rolf Markus, Dirschka, Thomas, Fargnoli, Maria Concetta, Gilaberte, Yolanda, Hædersdal, Merete, Chavda, Rajeev, Calzavara-Pinton, Piergiacomo, Szeimies, Rolf Markus, Dirschka, Thomas, Fargnoli, Maria Concetta, Gilaberte, Yolanda, Hædersdal, Merete, Chavda, Rajeev, and Calzavara-Pinton, Piergiacomo

Abstract

Methyl aminolevulinate (MAL) is a topical compound approved for use with photodynamic therapy (PDT) for the treatment of actinic keratosis (AK) and field cancerization in certain countries. There exists a high burden of disease for patients with AK: repeated treatments are required, there is a known risk of progression to keratinocyte carcinoma, and cosmetic appearance is affected. Delivery of PDT using MAL is a flexible treatment strategy available in many forms; red light, daylight, or artificial daylight can be used for illumination, all of which result in high AK clearance rates and low recurrence. MAL-PDT protocols continue to evolve to further improve adherence and treatment outcomes. Here, we used PubMed to search MEDLINE to identify guidelines, consensus recommendations, and studies describing the use of MAL for the treatment of AK. The aim of this targeted review is to consider various MAL-PDT treatment strategies on the basis of published literature, with a focus on personalizing treatment for the heterogeneous AK population., Methyl aminolevulinate (MAL) is a topical compound approved for use with photodynamic therapy (PDT) for the treatment of actinic keratosis (AK) and field cancerization in certain countries. There exists a high burden of disease for patients with AK: repeated treatments are required, there is a known risk of progression to keratinocyte carcinoma, and cosmetic appearance is affected. Delivery of PDT using MAL is a flexible treatment strategy available in many forms; red light, daylight, or artificial daylight can be used for illumination, all of which result in high AK clearance rates and low recurrence. MAL-PDT protocols continue to evolve to further improve adherence and treatment outcomes. Here, we used PubMed to search MEDLINE to identify guidelines, consensus recommendations, and studies describing the use of MAL for the treatment of AK. The aim of this targeted review is to consider various MAL-PDT treatment strategies on the basis of published literature, with a focus on personalizing treatment for the heterogeneous AK population.

Published
2023

24. Expert Recommendations on Facilitating Personalized Approaches to Long-term Management of Actinic Keratosis:The Personalizing Actinic Keratosis Treatment (PAKT) Project

Author

Morton, Colin, Baharlou, Samira, Basset-Seguin, Nicole, Calzavara-Pinton, Piergiacomo, Dirschka, Thomas, Gilaberte, Yolanda, Haedersdal, Merete, Hofbauer, Günther, Sapra, Sheetal, Waalboer-Spuij, Rick, Yip, Leona, Szeimies, Rolf Markus, Morton, Colin, Baharlou, Samira, Basset-Seguin, Nicole, Calzavara-Pinton, Piergiacomo, Dirschka, Thomas, Gilaberte, Yolanda, Haedersdal, Merete, Hofbauer, Günther, Sapra, Sheetal, Waalboer-Spuij, Rick, Yip, Leona, and Szeimies, Rolf Markus

Abstract

Actinic keratoses are pre-malignant skin lesions that require personalized care, a lack of which may result in poor treatment adherence and suboptimal outcomes. Current guidance on personalizing care is limited, nota-bly in terms of tailoring treatment to individual patient priorities and goals and supporting shared decision-making between healthcare professionals and patients. The aim of the Personalizing Actinic Keratosis Treatment panel, comprised of 12 dermatologists, was to identify current unmet needs in care and, using a modi-fied Delphi approach, develop recommendations to support personalized, long-term management of actinic ke-ratoses lesions. Panellists generated recommendations by voting on consensus statements. Voting was blinded and consensus was defined as ≥ 75% voting ’agree’ or ’strongly agree’. Statements that reached consensus were used to develop a clinical tool, of which, the goal was to improve understanding of disease chronicity, and the need for long-term, repeated treatment cy-cles. The tool highlights key decision stages across the patient journey and captures the panellist’s ratings of treatment options for attributes prioritized by patients. The expert recommendations and the clinical tool can be used to facilitate patient-centric management of ac-tinic keratoses in daily practice, encompassing patient priorities and goals to set realistic treatment expectations and improve care outcomes.

Published
2023

25. Long‐term efficacy and safety of 1% glycopyrronium bromide cream in patients with severe primary axillary hyperhidrosis: Results from a Phase 3b trial

Author

Szeimies, Rolf‐Markus, primary, Abels, Christoph, additional, Kilic, Ana, additional, Reich, Hubert, additional, Berger, Birgit, additional, Schulze zur Wiesche, Erik, additional, Schramm, Katharina, additional, Litzka, Leonie, additional, Heimstaedt‐Muskett, Susanne, additional, and Masur, Clarissa, additional

Published
2023
Full Text
View/download PDF

29. Photodynamic Therapy in Dermatology

Author

Szeimies, Rolf-Markus, Karrer, Sigrid, Abels, Christoph, Landthaler, Michael, Elmets, Craig A., Hönigsmann, Herbert, editor, Elmets, Craig A., editor, and Krutmann, Jean, editor

Published
2009
Full Text
View/download PDF

36. Mineralstoffwechselstöungen

Author

Szeimies, Rolf-Markus, Braun-Falco, Otto, editor, Plewig, Gerd, editor, Wolff, Helmut H., editor, Burgdorf, Walter H. C., editor, and Landthaler, Michael, editor

Published
2005
Full Text
View/download PDF

40. laser

Author

Kaudewitz, Peter, Drosner, Michael, Kimmig, Wolfgang, Raulin, Christian, Szeimies, Rolf-Markus, Plewig, Gerd, editor, and Degitz, Klaus, editor

Published
2001
Full Text
View/download PDF

41. Photodynamic Therapy in Dermatology

Author

Szeimies, Rolf-Markus, Karrer, Sigrid, Abels, Christoph, Landthaler, Michael, Elmets, Craig A., Krutmann, Jean, editor, Hönigsmann, Helmut, editor, Elmets, Craig A., editor, and Bergstresser, Paul R., editor

Published
2001
Full Text
View/download PDF

48. 2D luminescence imaging of pH in vivo

Author

Schreml, Stephan, Meier, Robert J., Wolfbeis, Otto S., Landthaler, Michael, Szeimies, Rolf-Markus, Babilas, Philipp, and Fuchs, Elaine

Published
2011

49. Indocyanine Green: Phototoxic Effects in vitro

Author

Fickweiler, Sonja, Szeimies, Rolf-Markus, Bäumler, Wolfgang, Steinbach, Pia, Karrer, Sigrid, Abels, Christoph, Hofstädter, Ferdinand, Landthaler, Michael, Waidelich, Wilhelm, editor, Waidelich, Raphaela, editor, and Waldschmidt, Jürgen, editor

Published
1998
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results